| Field | Specification |
|---|---|
| Target | |
| Alternative names | Acyl-CoA; 8-3; -desaturase; Delta(5) fatty acid desaturase; D5D; Delta(5) desaturase; Delta-5 desaturase; Fatty acid desaturase 1; FADS1; FADSD5 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human FADS1 recombinant protein (Position: M1-M257). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets acyl-CoA (gene FADS1) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 52.0 kDa, and the supplier reports an observed band at about 52 kDa.
FADS1 is the delta-5 fatty acid desaturase, an endoplasmic reticulum enzyme that inserts a double bond into polyunsaturated fatty acids. It converts dihomo-γ-linolenic acid to arachidonic acid and eicosatetraenoic acid to EPA, making it a key step in producing long-chain PUFAs and their lipid mediators; common FADS1 variants affect blood lipid levels.
| Target | Acyl-CoA (gene FADS1; UniProt O60427, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 52.0 kDa |
| Observed MW | 52 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.25 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human A549 cells, human Jurkat cells, human HeLa cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue, human lung cancer tissue, human ovarian cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human ovarian cancer tissue, human liver cancer tissue.
Samples with a confirmed signal (flow cytometry): SiHa cells.
Immunogen
Recombinant human FADS1 fragment (Met1–Met257), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. Tissue expression noted by UniProt (human): Widely expressed, with highest levels in liver, brain, adrenal gland and heart. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
